ArticleWorld journal of gastroenterology2012
Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients.
Article in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: an updated meta-analysis.PloS one · 2014Pooled it
- SASLT practice guidelines: management of hepatitis C virus infection.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2012Guideline
- New Approaches to Donor Selection and Preparation in Heart Transplantation.Current treatment options in cardiovascular medicine · 2021Review
- Hepatitis C virus infection in kidney transplantation-changing paradigms with novel agents.Hemodialysis international. International Symposium on Home Hemodialysis · 2018Review
- Donor selection in the modern era.Annals of cardiothoracic surgery · 2018Article
- Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up.Clinical and experimental nephrology · 2017Article
- Accepting Hearts From Hepatitis C-Positive Donor: Can We Expand the Donor Pool?Journal of cardiac failure · 2017Article
- Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon.World journal of gastroenterology · 2016Review
- Hepatitis C and its impact on renal transplantation.Nature reviews. Nephrology · 2015Review
- Management of patients with hepatitis C infection and renal disease.World journal of hepatology · 2015Review
- Management of hepatitis C in patients with chronic kidney disease.World journal of gastroenterology · 2015Review
- Kidney transplantation from donors with hepatitis C infection.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the efficacy and safety of combined pegylated interferon and ribavirin therapy in hepatitis C virus (HCV) infection in renal transplant recipients.
methodsThis is a retrospective chart review of post renal transplant patients who were positive for anti-HCV and HCV-RNA, and who have received treatment with combination of pegylated interferon and ribavirin between October 2003 and December 2008. Only patients with stable graft function and absence of evidence of cirrhosis and who received the therapy for continuous 48 wk were included. Nineteen patients (13 male and 6 female) were identified and included. The patient's complete blood count, liver and kidney profile, and calculated glomerular filtration rate (GFR) were monitored every 6-8 wk while on treatment. HCV-RNA was tested at 12 wk for early virological response, at 48 wk for end of treatment response (ETR), and then retested at 24, and 48 wk after completion of therapy for sustained virological response (SVR). Liver biopsies were obtained before treatment from all patients and graft kidney biopsies were performed as required.
resultsOf the entire cohort, 9 patients (47.4%) showed an ETR and 8 had SVR (42.1%). Of the 8 patients with abnormal alanine aminotransferase (ALT) levels at baseline, 78.9% had their ALT normalized (including the virological non responders). ALT was normal in all responders at the end of therapy and at 24 wk post therapy (100%). Only one patient (5.3%) developed an increase in creatinine and decline in GFR from baseline towards the end of treatment. This patient's kidney biopsy revealed borderline rejection. There was no impact on response by HCV-genotype, initial HCV RNA load, age or sex of the patient or duration post transplant before commencement of therapy. All patients tolerated treatment in the same way as non-transplant with no unusual or increased occurrence of side effects.
conclusionThe combination of pegylated interferon and ribavirin is effective in suppressing HCV-RNA, with a low risk of graft rejection or failure in HCV infected renal transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.